Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys

European Journal of Pharmacology

Volumn 378, Issue 2, 1999, Pages 169-175

  Ohmura, Tsuyoshi ^a   Chachin, Motohiko ^a   Tarui, Sachiyo ^a   Nagakura, Akihito ^a   Igarashi, Takashi ^a   Ikeda, Hironobu ^b   Ikegami, Kozaburo ^c   Kitagawa, Hisato ^a   Uchida, Shuji ^a  

^a Kawanishi Pharma Res Inst   (Japan)

^b Ukawa 555 Minakuchi Koka S   (Japan)

^c NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Astemizole; Cynomolgus monkey; ECG (electrocardiogram); Epinastine; Histamine H1 receptor antagonist; Terfenadine

Indexed keywords

ASTEMIZOLE; EPINASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; HEART ELECTROPHYSIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL;

ANIMALS; ARRHYTHMIA; ASTEMIZOLE; DIBENZAZEPINES; ELECTROCARDIOGRAPHY; HEART BLOCK; HISTAMINE H1 ANTAGONISTS; IMIDAZOLES; MACACA FASCICULARIS; MALE; TERFENADINE; TIME FACTORS;

EID: 0032788779     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00457-4     Document Type: Article

References (31)

1. Albengres E., Le Louet H., Tillement J.P. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18:1998;83-97.
2. Bazett H.C. Analysis of the times relations of electrocardiogram. Heart. 7:1920;353-370.
3. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am. J. Cardiol. 72:1993;50B-52B.
4. 1 receptor antagonists on HERG channels expressed in Xenopus oocytes. Comparative Studies of Epinastine, Terfenadine and Astemizole, Proceeding of the 2nd Conference on ABC Proteins and Ion Channels, p. 18.
5. Conti C.R. The nonsedating antihistamine scare. Clin. Cardiol. 17:1994;1.
6. 1-receptor antagonist treatment. J. Allergy Clin. Immunol. 86:1990;995-999.
7. Garteiz D.A., Hook R.H., Walker B.J. Pharmocokinetic and biotransformation studies of terfenadine in human. Arzneim.-Forsch./Drug Res. 32:1982;1185-1190.
8. 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br. J. Pharmacol. 119:1996;187-188.
9. Hey J.A., Del Prado M., Kreutner W., Egan R.W. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneim.-Forsch./Drug Res. 46:1996;159-163.
10. Honig P.K., Woosley R.L., Zamani K., Conner D.P., Cantilena L.R. Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:1992;231-238.
11. Honig P.K., Wortham D.C., Hull R., Zamani K., Smith J.E., Cantilena L.R. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33:1993;1201-1206.
12. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. J. Am. Med. Assoc. 269:1993;1513-1518.
13. Hsieh M.H., Chen S.A., Chiang C.E., Tai C.T., Lee S.H., Wen Z.C., Chang M.S. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int. J. Cardiol. 54:1996;85-88.
14. Kamei C., Mio M., Kitazumi K., Tsujimoto S., Yoshida T., Adachi Y., Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: II. Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol. Immunotoxicol. 14:1992;207-218.
15. 1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res. Commun. Mol. Pathol. Pharmacol. 98:1997;273-292.
16. Koh K.K., Rim M.S., Yoon J., Kim S.S. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. J. Electrocardiol. 27:1994;343-346.
17. Misawa M., Kanai Y., Chiba Y. Effects of the new antiallergic drug epinastine and ketotifen on repeated antigen challenge-induced airway hyperresponsiveness in rats. Arzneim.-Forsch./Drug Res. 41:1991;1277-1280.
18. Ohara N., Takizawa M., Yokota S., Katsumura H., Konishi C., Ishiguro Y., Shukunobe K., Kitagawa H. General pharmacology of epinastine hydrochloride (WAL 801 CL), an antiallergic agent. Jpn. Pharmacol. Ther. 20:1992;63-90.
19. Ohtani H., Kotaki H., Sawada Y., Iga T. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J. Pharm. Pharmacol. 49:1997;458-462.
20. Roy M., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the nonsedating antihistamine. Circulation. 94:1996;817-823.
21. 1 receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ. Res. 76:1995;110-119.
22. Smith S.J. Cardiovascular toxicity of antihistamines. Otolaryngol. -Head Neck Surg. 111:1994;348-354.
23. Tasaka K., Kamei C., Nakamura S. Inhibitory effect of epinastine on bronchoconstriction induced by histamine, platelet activating factor and serotonin in guinea pigs and rats. Arzneim.-Forschung./Drug Res. 44:1994;327-329.
24. Tran H.T. Torsades de pointes induced by nonantiarrhythmic drugs. Conn. Med. 58:1994;291-295.
25. Tsai W.C., Tsai L.M., Chen J.H. Combined use of astemizole and ketoconazole resulting in torsade de pointes. J. Formosan Med. Assoc. 96:1997;144-146.
26. Vella S., Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin. Pharmacokinet. 34:1998;189-201.
27. Vorperian V.R., Zhou Z., Mohammad S., Hoon T.J., Studenik C., January C.T. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J. Am. Coll. Cardiol. 28:1996;1556-1561.
28. Woosley R.L. Cardiac actions of antihistamines. Annu. Rev. Pharmacol. Toxicol. 36:1996;233-252.
29. Zechnich A.D., Hedges J.R., Eiselt-Proteau D., Haxby D. Possible interactions with terfenadine or astemizole. West. J. Med. 160:1994;321-325.
30. Zhang M.Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr. Med. Chem. 4:1997;187.
31. Zimmermann M., Duruz H., Guin O., Broccard O., Levy P., Lacatis D., Bloch A. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. 13:1992;1002.